RS 601

Drug Profile

RS 601

Latest Information Update: 15 Feb 2008

Price : $50

At a glance

  • Originator Hokuriku Seiyaku
  • Class Antiasthmatics; Butyric acids; Small molecules; Sulfonamides
  • Mechanism of Action Leukotriene D4 receptor antagonists; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 13 Mar 2001 Pharmaceutical business of BASF has been acquired by Abbott Laboratories
  • 17 Aug 1998 Preclinical development for Asthma in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top